David Novak

Item: David Novak
Rating: 0.56
Author: StockAnalysis.com

Stock Analyst at Raymond James

(0.56)

# 4,173

Out of 5,131 analysts

Total ratings

42.86%

Success rate

-13.85%

Average return

Main Sectors:

Top Industries:

Stocks Rated by David Novak

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	ZYME Zymeworks	Downgrades: Outperform	$74	$23.16	+219.52%	6	Dec 10, 2021
	CBIO Crescent Biopharma	Maintains: Outperform	$300 → $270	$10.98	+2,359.02%	1	Feb 4, 2021

Zymeworks

Dec 10, 2021

Downgrades: Outperform

Price Target: $74

Current: $23.16

Upside: +219.52%

Crescent Biopharma

Feb 4, 2021

Maintains: Outperform

Price Target: $300 → $270

Current: $10.98

Upside: +2,359.02%